FDA Decision on Zepbound for Sleep Apnea Expected Soon
Eli Lilly Seeks FDA Approval for Zepbound in Sleep Apnea Treatment Eli Lilly has filed a U.S. application to treat obstructive sleep apnea (OSA) with its weight-loss medication Zepbound. Promising outcomes from two late-stage trials led to this action. The company wants to fill a big unmet need in sleep disorder therapies. Zepbound might give OSA sufferers a new choice if it is approved. Treatment options are few and frequently laborious at the moment. The world of sleep apnea tre
Continue Reading